Studies conducted by Yang et al. [141] and Ha et al. [142] ascertained that a high grade or score of the pre-treatment serum ALB–BIL combined withpre-treatment systemic immune-inflammation index (SII) was independently correlated with worse OS, RFS, and cancer-specific survival (CSS) in HCC patients treated with RFA, PMWA, or TACE. Here, ALB is linked to hepatocellular carcinoma.